People: TranS1 Inc. (TSON.O)

TSON.O on Consolidated Issue listed on NASDAQ Global Market

--USD
--
Price Change (% chg)

-- (--)
Prev Close
$3.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
32,270
52-wk High
$8.74
52-wk Low
$3.01

view people for:

Summary

Name Age Since Current Position
Randall, Richard 56 2010 Chief Executive Officer, Director
Reali, Ken 44 2010 President, Chief Operating Officer
Luetkemeyer, Michael 59 2007 Chief Financial Officer
Simmons, Ricardo 46 2003 Vice President - Marketing and Sales
Martin, Robert 44 2007 Vice President - International Sales
Carusi, Michael 43 2003 Director
Dann, Mitchell 49 2000 Director
Osgood, Jonathan 59 2002 Director
Shapiro, James 50 2005 Director
Slattery, Joseph 44 2007 Director
LaViolette, Paul 51 2008 Director
» Insider Trading

Biographies

Name Description
Randall, Richard Mr. Richard Randall has been Chief Executive Officer and a member of Board of Directors of TranS1 Inc. since June 2002. He had also been President of the Company. From June 2000 to June 2002, Mr. Randall served as President and Chief Executive Officer of Incumed, Inc., a privately-held medical device incubator company. He was President, Chief Executive Officer and a director of Innovasive Devices, Inc., a developer, manufacturer and marketer of arthroscopic surgical products which was acquired by the Ethicon Division of Johnson & Johnson in 2000, from January 1994 to February 2000. Mr. Randall served as President and Chief Executive Officer of Conceptus, Inc. from December 1992 to July 1993 and Chief Financial Officer from December 1992 to January 1995. He served as President and Chief Executive Officer of Target Therapeutics, Inc., an interventional neurovascular medical device company which was acquired by Boston Scientific Corporation in 1997, from June 1989 to May 1993 and was a director of Target Therapeutics from June 1989 to April 1997. Mr. Randall received a B.S. degree in Biology and Science Education from State University College of New York at Buffalo.
Reali, Ken Mr. Ken Reali has been appointed as President and Chief Operating Officer of TranS1 Inc. Mr. Reali has over 20 years of general management, sales and marketing experience with medical device and orthopedic companies. Mr. Reali joined the Company from Smith & Nephew where he spent five years in various senior marketing, sales and product development positions, including most recently as Senior Vice President and General Manager of the Biologics and Spine Business. Prior to joining Smith & Nephew, Mr. Reali held senior marketing, sales and product development positions at Stryker for seven years. Prior to joining Stryker, Mr. Reali worked as a territory and product manager at BioMet for eight years. Mr. Reali received a B.S. degree in Business from Valparaiso University.
Luetkemeyer, Michael Mr. Michael Luetkemeyer has been Chief Financial Officer of TranS1 Inc. since April 2007. Prior to that, Mr. Luetkemeyer held various positions with Micromuse, Inc., a network management software provider that was acquired by IBM in 2006, including Chief Financial Officer from October 2001 to January 2005, interim Chief Executive Officer from January 2003 to August 2003, and Senior Vice President from February 2005 to March 2006. Mr. Luetkemeyer also served as a member of the board of directors of Micromuse from January 2003 to February 2005. Prior to joining Micromuse, he served as Chief Financial Officer of Aprisma Management Technologies, a network management software provider, from 2000 until October 2001, and held a variety of senior finance positions at GE Aerospace, GE Semiconductor and GE Plastics for more than ten years. Mr. Luetkemeyer received a B.S. degree in Finance from Southwest Missouri State, an M.A. degree in Economics from the University of Missouri (St. Louis) and a B.S. degree in Accounting from Rollins College.
Simmons, Ricardo Mr. Ricardo Simmons has been Vice President, Marketing and Sales of TranS1 Inc. since November 2003. From 2000 to 2003 Mr. Simmons served as Vice President of Sales and Marketing at Nuvasive, Inc., a publicly traded minimally invasive spinal platform technology and implant company. From 1997 to 2000, he served as Vice President, Global Marketing and Sales of Innovasive Devices, Inc., a developer, manufacturer and marketer of arthroscopic surgical products which was acquired by the Ethicon Division of Johnson & Johnson in 2000. From 1995 to 1997, Mr. Simmons served as Director of Marketing, Managed Care and Business Development of Genzyme Tissue Repair, Inc., a human tissue engineering technology company serving the orthopaedic surgical sports medicine market and publicly traded division within Genzyme Corporation. Mr. Simmons received a B.A. degree in Exercise Physiology from the California State University at Northridge.
Martin, Robert Mr. Robert Martin has been Vice President of International Sales of TranS1 Inc. since July 2007. From 2000 to June 2007, Mr. Martin served as Vice President of Global Sales and Marketing and, most recently, as President and CEO at Ascension Orthopedics Inc., a privately held extremity orthopedics company. From 1999 to 2000, he served as European Sales Manager for Innovasive Devices, Inc. a developer, manufacturer, and marketer of arthroscopic surgical products which was acquired by the Ethicon Division of Johnson & Johnson in 2000. From 1996 to 1999, Mr. Martin served as Sales and Marketing Manager for three divisions of Stryker Inc. (Canada), a publicly traded global orthopedic company. Mr. Martin received a B.A. degree in Physical Education from the University of Western Ontario.
Carusi, Michael Mr. Michael Carusi has served as a member of Board of Directors of TranS1 Inc. since April 2003. He has served as a General Partner at Advanced Technology Ventures, a venture capital firm, since October 1998. Mr. Carusi serves on the board of directors of XTENT, Inc., a publicly traded medical device company, as well as the boards of several privately-held life sciences and medical device companies. Mr. Carusi received a B.S. degree in Mechanical Engineering from Lehigh University and an M.B.A. degree from the Amos Tuck School of Business at Dartmouth College.
Dann, Mitchell Mr. Mitchell Dann has served as a member of Board of Directors of TranS1 Inc. since September 2000. Mr. Dann is the founder and managing member of Sapient Capital Management, LLC, the general partner of the general partner of Sapient Capital, L.P., a venture capital firm specializing in the medical device industry. Previously, Mr. Dann was President of M. Dann & Co., Inc., a venture capital advisory firm, and was a co-founder of Urologix, Inc., a publicly traded medical device company (NASDAQ: ULGX), where he served as a director from 1991 until 2005, including as Chairman of the Board from 1993 until 2003. In February 2008, Mr. Dann was re-named Chairman of the Board of Urologix, Inc. Mr. Dann also serves as a member of the board of directors of several privately-held medical device companies. Mr. Dann received a B.S. degree in Engineering from the University of Vermont.
Osgood, Jonathan Mr. Jonathan Osgood has served as a member of Board of Directors of TranS1 Inc. since March 2002. In 2001, Mr. Osgood co-founded, and is the managing member of, Cutlass Capital, L.L.C., a venture capital firm that invests exclusively in the healthcare industry. Mr. Osgood also serves as a member of the board of directors of several privately-held medical device companies. Mr. Osgood is a Certified Financial Analyst and received a B.A. degree in Economics from Dartmouth College and an M.B.A. degree from the Amos Tuck School of Business at Dartmouth College.
Shapiro, James Mr. James Shapiro has served as a member of Board of Directors of TranS1 Inc. since September 2005. Mr. Shapiro has served as a General Partner of Kearny Venture Partners, a venture capital firm, and its predecessor, Thomas Weisel Healthcare Venture Partners, since March 2003. Since January 2000, Mr. Shapiro has also been a General Partner of ABS Healthcare Ventures. Mr. Shapiro serves on the board of directors of Hansen Medical, Inc., a publicly traded medical device company, as well as on the boards of several privately-held medical device companies. Mr. Shapiro received an A.B. degree from Princeton University and an M.B.A degree from the Stanford University Graduate School of Business.
Slattery, Joseph Mr. Joseph Slattery has served as a member of Board of Directors of TranS1 Inc. since November 2007. From October 1, 2006 through August 3, 2007, Mr. Slattery served as Chief Financial Officer and Senior Vice President of Finance and Information Systems of Digene Corporation, a molecular diagnostics company that was acquired by Qiagen, N.V. in August, 2007. Prior to being appointed Chief Financial Officer, he served as Senior Vice President, Finance and Information Systems beginning in September 2002. Previously, he served as Vice President, Finance from July 1999 to September 2002 and as Controller from February 1996 to July 2000. Mr. Slattery serves on the board of directors of Micromet, Inc., a publicly-held biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases and CVRx, Inc. a privately-held company developing implantable technology for the treatment of hypertension. Mr. Slattery received a B.S. degree in Accountancy from Bentley University.
LaViolette, Paul Mr. Paul LaViolette has served as a member of Board of Directors of TranS1 Inc. since August 2008. Mr. LaViolette became a venture partner at SV Life Sciences in January 2009 and brings over 28 years of global medical technology marketing and general management experience. He was most recently Chief Operating Officer at Boston Scientific Corporation (“BSC”), an $8 billion medical device leader. During his 15 years at BSC, he served as Chief Operating Officer, Group President, President-Cardiology and President-International as the company grew revenues over 20 times. Mr. LaViolette integrated two dozen acquisitions and led extensive product development, operations and worldwide commercial organizations. He previously held marketing and general management positions at CR Bard, and various marketing roles at Kendall (Tyco). He previously served on the boards of Urologix, Percutaneous Valve Technologies and AdvaMed, and currently serves on the boards of Direct Flow Medical, Cameron Health, Conceptus, DJO Global and Thoratec. Mr. LaViolette received a B.A degree in Psychology from Fairfield University and an M.B.A. degree from Boston College.

Basic Compensation

Name Fiscal Year Total
Randall, Richard 498,764
Reali, Ken --
Luetkemeyer, Michael 598,893
Simmons, Ricardo 411,222
Martin, Robert 419,730
Carusi, Michael --
Dann, Mitchell --
Osgood, Jonathan --
Shapiro, James --
Slattery, Joseph --
LaViolette, Paul --
As Of 30 Dec 2008

Insider Trading

Name Shares Traded Price
DANN MITCHELL 1,700 $4.01
DANN MITCHELL 10,800 $4.00
DELPHI MANAGEMENT PARTNERS VIII L L C 1,450 $4.69
DELPHI MANAGEMENT PARTNERS VIII L L C 148,550 $4.69
DELPHI MANAGEMENT PARTNERS VIII L L C 629 $4.61
DELPHI MANAGEMENT PARTNERS VIII L L C 64,371 $4.61
DELPHI MANAGEMENT PARTNERS VIII L L C 87 $4.99
DELPHI MANAGEMENT PARTNERS VIII L L C 8,913 $4.99
DELPHI MANAGEMENT PARTNERS VIII L L C 387 $4.89
DELPHI MANAGEMENT PARTNERS VIII L L C 39,613 $4.89
DELPHI MANAGEMENT PARTNERS VIII L L C 9,903 $5.96
DELPHI MANAGEMENT PARTNERS VIII L L C 97 $5.96
DELPHI MANAGEMENT PARTNERS VIII L L C 145 $5.91
DELPHI MANAGEMENT PARTNERS VIII L L C 14,855 $5.91
DELPHI MANAGEMENT PARTNERS VIII L L C 306 $5.98
DELPHI MANAGEMENT PARTNERS VIII L L C 31,294 $5.98
DELPHI MANAGEMENT PARTNERS VIII L L C 387 $5.98
DELPHI MANAGEMENT PARTNERS VIII L L C 39,613 $5.98
DELPHI MANAGEMENT PARTNERS VIII L L C 629 $5.97
DELPHI MANAGEMENT PARTNERS VIII L L C 64,371 $5.97
DELPHI MANAGEMENT PARTNERS VIII L L C 1,112 $5.86
DELPHI MANAGEMENT PARTNERS VIII L L C 113,888 $5.86
DELPHI MANAGEMENT PARTNERS VIII L L C 198,066 $5.88
DELPHI MANAGEMENT PARTNERS VIII L L C 1,934 $5.88
DELPHI MANAGEMENT PARTNERS VI L L C 483 $5.90
» Full list on Insider Trading
view people for: